Erik S Blomain
Overview
Explore the profile of Erik S Blomain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
The NorCal brachytherapy waste audit: A simple, validated, toolkit for clinician led waste reduction
Baniel C, Lichter K, Frick M, Wu J, Oladipo E, Wu Y, et al.
Brachytherapy
. 2025 Mar;
PMID: 40024828
Purpose: The healthcare system is resource intensive, and many opportunities exist to reduce medical waste. Brachytherapists performing inherently resource intensive procedures are well poised to initiate the transition to sustainable,...
2.
Blomain E, Blomain E, Soudi S, Wang Z, Somani A, Subramanian A, et al.
Cancer Res
. 2025 Jan;
85(6):1162-1174.
PMID: 39808162
Radiotherapy is an integral component in the treatment of many types of cancer, with approximately half of patients with cancer receiving radiotherapy. Systemic therapy applies pressure that can select for...
3.
Ngo N, Blomain E, Simiele E, Romero I, Hoppe R, Hiniker S, et al.
Pediatr Blood Cancer
. 2023 Jul;
70(10):e30589.
PMID: 37486149
Purpose/objectives: To evaluate dosimetric differences between auto-planned volumetric modulated arc therapy (VMAT) total body irradiation (TBI) technique and two-dimensional radiotherapy using anterior-posterial/posterio-anterial beams (2D AP/PA) TBI technique. Methods: Ten pediatric...
4.
Blomain E, Jiang A, Donaldson S, Agarwal R, Bertaina A, Shyr D, et al.
Adv Radiat Oncol
. 2022 Dec;
8(1):101071.
PMID: 36483061
Purpose: Children with leukemia who receive fractionated total body irradiation (fTBI) with 12 to 13.2 Gy as part of conditioning for hematopoietic stem cell transplant are frequently treated with an...
5.
Blomain E, Moding E
Int J Mol Sci
. 2021 Oct;
22(20).
PMID: 34681925
Molecular alterations drive cancer initiation and evolution during development and in response to therapy. Radiotherapy is one of the most commonly employed cancer treatment modalities, but radiobiologic approaches for personalizing...
6.
Blomain E, Kovalchuk N, Neilsen B, Skinner L, Hoppe R, Hiniker S
Pract Radiat Oncol
. 2020 Aug;
11(2):e134-e138.
PMID: 32795616
Reproductive toxicity is common after total body irradiation (TBI) and has major quality of life implications for patients. In that context, this is the first report of gonadal-sparing volumetric-modulated arc...
7.
Blomain E, Rappaport J, Pattison A, Bashir B, Caparosa E, Stem J, et al.
Cancer Biol Ther
. 2020 Feb;
21(5):441-451.
PMID: 32037952
Sporadic colorectal cancer initiates with mutations in APC or its degradation target β-catenin, producing TCF-dependent nuclear transcription driving tumorigenesis. The intestinal epithelial receptor, GUCY2C, with its canonical paracrine hormone guanylin,...
8.
Shi W, Blomain E, Siglin J, Palmer J, Dan T, Wang Y, et al.
J Neurooncol
. 2018 Jan;
137(1):179.
PMID: 29313182
The fourth author's name was incorrect in the initial online publication. The original article has been corrected.
9.
Shi W, Blomain E, Siglin J, Palmer J, Dan T, Wang Y, et al.
J Neurooncol
. 2017 Dec;
137(1):171-177.
PMID: 29235052
Bevacizumab failure is a major clinical problem in the management of high grade gliomas (HGG), with a median overall survival (OS) of < 4 months. This study evaluated the feasibility...
10.
Pattison A, Merlino D, Blomain E, Waldman S
World J Gastroenterol
. 2016 Oct;
22(36):8070-7.
PMID: 27688649
Colorectal cancer (CRC) is a major cause of cancer-related mortality and morbidity worldwide. While improved treatments have enhanced overall patient outcome, disease burden encompassing quality of life, cost of care,...